Vanda: A Long-Term Pharma Growth Idea, Despite Q1 Earnings Miss (NASDAQ:VNDA)
· seekingalpha.com
Vanda Pharmaceuticals (VNDA) buy case: new drug approvals, pipeline, and growth catalysts vs. cash burn, losses, and neutral chart setup.
Albert Anthony is the pen name of a business author on Amazon and his newest book is "How To Pick Stocks: 8 Steps For Long-Term Investing with Fundamental & Tec...